Diagnostic and Prognostic Value of Ergonovine Echocardiography for Noninvasive Diagnosis of Coronary Vasospasm

This study sought to obtain large-scale evidence supporting the clinical usefulness of ergonovine echocardiography. The role of noninvasive ergonovine provocation testing with echocardiographic monitoring of ventricular wall motion (ergonovine echocardiography) needs to be defined. Clinical data of...

Full description

Saved in:
Bibliographic Details
Published in:JACC. Cardiovascular imaging 2020-09, Vol.13 (9), p.1875-1887
Main Authors: Om, Sang Yong, Yoo, Sang-Yong, Cho, Goo-Yeong, Kim, Minsoo, Woo, Yeongmin, Lee, Sahmin, Kim, Dae-Hee, Song, Jong-Min, Kang, Duk-Hyun, Cheong, Sang Sig, Park, Seong-Wook, Park, Seung-Jung, Song, Jae-Kwan
Format: Article
Language:English
Subjects:
coronary vasospasm
echocardiography
ergonovine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study sought to obtain large-scale evidence supporting the clinical usefulness of ergonovine echocardiography. The role of noninvasive ergonovine provocation testing with echocardiographic monitoring of ventricular wall motion (ergonovine echocardiography) needs to be defined. Clinical data of patients who underwent ergonovine echocardiography in 3 tertiary referral hospitals in South Korea were analyzed. Ergonovine echocardiography was performed in 14,012 patients (mean age 52.8 ± 11.1 years; 6,213 [44.3%] women) after exclusion of significant coronary arterial stenosis by functional (treadmill or perfusion scan, n = 9,824) or anatomic test (invasive or computerized tomographic coronary angiography, n = 4,188). Premature termination developed in 0.4% (n = 51), and a positive result was observed in 2,144 patients (15.3%), with variable frequencies according to the diagnosis (acute coronary syndrome [38.2%], variant angina [31.8%], effort angina [14.9%], aborted sudden cardiac death [17.6%], syncope [9.9%]). There was no mortality or development of myocardial infarction during the test. During median follow-up of 11.4 (interquartile range: 7.2 to 15.8) years, death of any cause and cardiovascular death occurred in 494 and 143 patients, respectively. The 10-year overall (96.7 ± 0.2% vs. 91.5 ± 0.6%; p 
ISSN:1936-878X
1876-7591
DOI:10.1016/j.jcmg.2020.03.008